Live Analyst Rating Changes 23588 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Seiji Wakao
JPM

Seiji Wakao

J.P. Morgan
Wall Street Analyst
★★★☆☆
#2139
on 13Foresight · ranked by our own returns
50%
Success Rate
+7.8%
Average Return
8 of 16 calls profitable · -8.9% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 50% of Seiji Wakao's ratings turned a profit when each position was held for 1 year — averaging +7.8% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

7 Buy 3 Hold 1 Sell
Seiji's Stock Coverage 16 ratings · 2026-08-12
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
JP:4568
Daiichi Sankyo Company
 Jun 04, 2026 HOLD Strong Buy
+57.7% avg upside
7 analysts
$2750.00
1.54% Downside
 +10.5% ·
JP:4151
Kyowa Kirin Co
 Mar 03, 2026 SELL Sell
-18.0% avg upside
5 analysts
$1800.00
30.39% Downside
 -15.7% ·
JP:4519
Chugai Pharmaceutical Co
 Feb 06, 2026 BUY Strong Buy
+34.7% avg upside
6 analysts
$10700.00
52.11% Upside
 -24.2% ·
JP:4506
Sumitomo Dainippon Pharma Co
 Sep 05, 2025 BUY Buy
+32.6% avg upside
4 analysts
$1880.00
40.65% Upside
 -27.8% ·
JP:4523
Eisai Co
 Sep 04, 2025 HOLD Buy
+2.3% avg upside
6 analysts
$4900.00
0.09% Upside
 -4.0% ·
JP:4503
Astellas Pharma
 Sep 04, 2025 HOLD Buy
-7.9% avg upside
6 analysts
$1900.00
19.46% Downside
 +42.2% ·
JP:4516
Nippon Shinyaku Co., Ltd.
 Jul 22, 2025 HOLD Buy
+8.9% avg upside
4 analysts
$3200.00
11.88% Downside
 +28.6% ·
JP:4578
Otsuka Holdings Co
 Jul 15, 2025 BUY Strong Buy
-5.6% avg upside
7 analysts
$11000.00
13.76% Downside
 +70.2% ·
JP:4528
ONO Pharmaceutical Co
 Jul 15, 2025 SELL Sell
-23.4% avg upside
3 analysts
$1300.00
45.90% Downside
 -47.0% ·
JP:4536
Santen Pharmaceutical Co
 Jun 12, 2025 BUY Strong Buy
+17.6% avg upside
3 analysts
$2600.00
33.30% Upside
 +16.4% ·
JP:6523
PHC Holdings Corp.
 Apr 08, 2025 HOLD Hold
-27.3% avg upside
2 analysts
$1000.00
25.69% Downside
 +30.7% ·
JP:4502
Takeda Pharmaceutical Co
 Mar 27, 2025 HOLD Strong Buy
-0.3% avg upside
8 analysts
$4500.00
19.16% Downside
 +33.8% ·
JP:4507
Shionogi & Co
 Mar 27, 2025 HOLD Buy
-4.1% avg upside
6 analysts
$2200.00
22.96% Downside
 +54.3% ·
JP:4565
Sosei Group
 Oct 24, 2024 BUY Strong Buy
+67.7% avg upside
2 analysts
$1800.00
95.62% Upside
 -16.5% ·
JP:4901
FUJIFILM Holdings
 Aug 26, 2024 BUY Strong Buy
+42.8% avg upside
3 analysts
$5000.00
56.22% Upside
 -4.9% ·
TAK
Takeda Pharmaceutical Company
 Sep 13, 2021 HOLD Strong Buy
+11.4% avg upside
5 analysts
$18.00
3.20% Upside
 -21.3% ·
🔒 11 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Seiji Wakao — Frequently Asked Questions
How accurate are Seiji Wakao's stock ratings?
Based on the calls 13Foresight could measure, about 50% of Seiji's ratings were profitable over a one-year hold, with an average return of +7.8% per rating, or -8.9% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Seiji ranked on 13Foresight?
Seiji Wakao is currently ranked #2139 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Seiji cover?
Seiji most recently has ratings on JP:4568, JP:4151, JP:4519, JP:4506, JP:4523, JP:4503, JP:4516, JP:4578, JP:4528, JP:4536, JP:6523, JP:4502 and 4 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.